Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings. In this study, we report the identification and biological characterization of X-376 and X-396, two potent and highly specific ALK small molecule tyrosine kinase inhibitors (TKIs). In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clinical trials. Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles. Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein. Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations associated with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant. Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin. Our findings offer preclinical proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.

[1]  P. Jänne,et al.  Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. , 2010, Cancer research.

[2]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[3]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[4]  P. Jänne,et al.  The biology and treatment of EML4-ALK non-small cell lung cancer. , 2010, European journal of cancer.

[5]  W. Pao,et al.  High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer , 2010, Journal of Neuro-Oncology.

[6]  P. Sabbatini,et al.  GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers , 2009, Molecular Cancer Therapeutics.

[7]  W. Pao,et al.  EML4-ALK: honing in on a new target in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Ratain,et al.  Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  U. Müller-Vieira,et al.  An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells. , 2009, Toxicology and applied pharmacology.

[10]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[11]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[12]  G. Neri,et al.  Faculty Opinions recommendation of Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. , 2009 .

[13]  Michael Peyton,et al.  Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines , 2009, PloS one.

[14]  Y. Ishikawa,et al.  A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.

[15]  N. Rosen,et al.  HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells , 2008, Molecular Cancer Therapeutics.

[16]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[17]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[18]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[19]  Y. Ishikawa,et al.  Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.

[20]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[21]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[22]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[23]  A. Iafrate,et al.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.

[24]  John C. Boik,et al.  Quantifying synergism/antagonism using nonlinear mixed‐effects modeling: A simulation study , 2008, Statistics in medicine.

[25]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[26]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[27]  P. Włodarski,et al.  Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway , 2007, Oncogene.

[28]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[29]  M. Meyerson,et al.  Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors , 2007, Cancer biology & therapy.

[30]  Shinji Yamazaki,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.

[31]  Peter G. Schultz,et al.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.

[32]  P. Jänne,et al.  Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations , 2005 .

[33]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[34]  A. Ullrich,et al.  Strategies to overcome resistance to targeted protein kinase inhibitors , 2004, Nature Reviews Drug Discovery.

[35]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. D. Dal Cin,et al.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. , 2000, The American journal of pathology.

[37]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[38]  H. Lodish,et al.  Characterization of the asialoglycoprotein receptor in a continuous hepatoma line. , 1981, The Journal of biological chemistry.

[39]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[40]  P. Jänne,et al.  Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. , 2005, Journal of the National Cancer Institute.

[41]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.